Target intelligence / Profile preview

Argonaute/RNA-induced silencing complex (RISC)

Target
RISC
Molecular classification
Ribonucleoprotein complex, Enzyme, Other
01

Overview

The Argonaute/RNA-induced silencing complex (RISC) is a multi-protein ribonucleoprotein complex that plays a central role in post-transcriptional gene silencing via the RNA interference (RNAi) pathway. The core catalytic component of RISC is an Argonaute protein (primarily AGO2 in humans), which binds a single-stranded small RNA guide (such as a microRNA or small interfering RNA) to recognize and cleave complementary messenger RNA (mRNA) transcripts, or otherwise repress their translation. In its physiological state, the Argonaute/RISC complex regulates cellular homeostasis, development, and defense against viral infections by modulating gene expression. Dysregulation of endogenous RISC components or microRNA pathways is implicated in various diseases, including cancers, cardiovascular disorders, and genetic diseases.

In therapeutics, the Argonaute/RISC complex is co-opted by synthetic small interfering RNA (siRNA) drugs to achieve highly specific, long-lasting knockdown of disease-causing genes. Upon delivery into the cytoplasm, double-stranded siRNA drugs are loaded into the complex, where the passenger strand is discarded, and the guide strand directs AGO2 to cleave the target mRNA. This mechanism has been successfully leveraged by several FDA-approved therapeutics, such as patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran, to treat conditions ranging from hereditary transthyretin-mediated amyloidosis to hypercholesterolemia.

Other names
RNA-induced silencing complexRISCArgonaute-RISC complexAGO-RISC complexArgonaute-containing RNA-induced silencing complexmiRISC
02

Mechanism of action

siRNA or miRNA loading into the RISC complex, followed by passenger strand cleavage/discarding, and guide strand-mediated complementary mRNA targeting and cleavage by Argonaute (specifically AGO2).

03

Biological functions

Gene silencingRNA interferencePost-transcriptional gene regulationmRNA cleavageTranslational repression
04

Disease associations

Genetic disorderCardiovascular diseaseInfectionCancerOther
05

Safety considerations

Off-target gene silencingSaturation of endogenous RNAi machineryImmunogenicity/activation of innate immune receptors (TLRs)Hepatotoxicity (for liver-targeted siRNAs)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Target mRNA levelsTarget protein levelssiRNA concentration in tissue

Beyond the preview

Go deeper on Argonaute/RNA-induced silencing complex (RISC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argonaute/RNA-induced silencing complex (RISC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call